Oliver Jonas
Papers
2
Total Citations
9
H-Index
2
About
Oliver Jonas is a pioneer in precision oncology, specializing in the development of implantable microdevices (IMDs) for real-time, in situ drug sensitivity testing. His major contribution is the creation of a novel platform that allows multiple chemotherapeutic and systemic agents to be delivered directly into a tumor microenvironment, enabling personalized treatment selection without systemic toxicity. In his landmark 2022 study, Jonas demonstrated the first-in-human intrathoracic implantation of a multidrug-eluting microdevice in nonsmall cell lung cancer (NSCLC) patients undergoing operative resection, proving safety and feasibility (7 citations). He extended this concept to prostate cancer in 2024, achieving percutaneous MR-guided implantation in intermediate- and high-risk patients, again confirming safety and the ability to assess intratumor drug response (2 citations). These works represent a paradigm shift from empirical to evidence-based adjuvant therapy, potentially sparing patients from ineffective treatments. Jonas’s research bridges engineering, radiology, and oncology, and his microdevice technology has been recognized as a breakthrough for functional precision medicine. His work continues to shape the future of personalized cancer therapy.
Research Focus
Key Achievements
Top Papers
- 1
- 2